ABOUT MILTENYI BIOTEC
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
FEATURED CONTENT
-
Flow cytometry compensation is critical, for it directly impacts data accuracy and quality. Here, we share eight tips to improve compensation in multicolor flow experiments.
-
Learn the 4 physical conditions that occur during droplet sorting, which may keep your cells from being happy.
-
Here, we demonstrate the capacity of a specific bench top sorter to allow for completely aseptic sorting conditions by using the system to sort cancer antigen-specific cytotoxic T cells out of PBMCs.
-
Isolating fully functional CAR T cells requires high quality cell separation. See how we successfully and efficiently isolated CD19 CAR T cells with the MACSprep™ CD19 CAR MicroBead Kit, human.
-
Learn how the knowledge generated by a deep and thorough analysis of chemokine receptors on natural killer (NK) cells can be helpful to scientists studying certain cancers and diseases.
-
Here, we describe the multicolor flow cytometry analysis necessary to study natural killer (NK) cell phenotype and the function of isolated NK cells from whole blood.
-
Here, we show an automated experimental setup for human CD34+ HSC enrichment from umbilical cord blood for the successful generation of humanized mouse models.
-
Research is being done to study a new method for isolating TILs from human colon tumor xenografts that could be more efficient and effective than traditional methods.
-
Explore results from a study that utilized an in vivo model to assess the antibody-dependent cellular cytotoxicity (ADCC) activity of antibodies to clear HIV-infected cells.
-
High-quality automated cell isolation and consistent cell culture and stimulation conditions are required for successful immuno-oncology studies. See how CD8+ T cells and XP-DCs were isolated using MACS® technology.
-
Explore results from using both flow cytometry and the LDH assay for the isolation of NK cells and an ADCC assay with the MultiMACS™ Cell24 Separator Plus.
-
Analyze an experiment conducted to validate a macrophage suppression assay workflow and demonstrate a consistent in vitro macrophage suppression assay used in the validation process.
-
Explore the steps involved and the products used in the generation of functional monocyte-derived DCs (Mo-DCs) that are suitable for a variety of research and immunotherapy applications.
-
To validate the importance of using an automated PI staining process with a MACSQuant® Flow Cytometer, we processed various 96-well plates of Jurkat cells under different conditions.
-
Here, we compare two methods for the dissociation of renal tumor tissue to obtain TILs: a novel, combined mechanical/enzymatic, automated 3-hour process versus an established overnight digestion protocol.
-
Successful cell sorting relies on the collection of viable cells, and new technology is being designed to address cell sorting concerns, such as cell damage and sterility.
-
Here, we demonstrate the ability of a fully closed, sterile cell sorter to sort rare antigen-specific cytotoxic T cells out of fresh peripheral blood mononuclear cells (PBMCs).
-
Look further into the study of a new workflow for the isolation and analysis of tumor-infiltrating lymphocytes to see how it could become a valuable tool for immunotherapy researchers.
-
Here, we demonstrate the generation of large numbers of CD8+CD137+ antigen-specific T cells with high purity based on GMP-compatible reagents and sorting system.
-
Unprecedented efficacy in targeting cancer has been demonstrated with CAR T-cell therapy. Discover a device that allows the generation of CAR T-cells in a single automated and closed system.
CONTACT INFORMATION
Miltenyi Biotec
12740 Earhart Ave.
Auburn, CA 95602
UNITED STATES